Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Controlled Trial Comparing Vonoprazan Triple Therapy (Vonoprazan, Amoxicillin, Clarithromycin), and Standard Triple Therapy (Esomeprazole, Amoxicillin, Clarithromycin) for Helicobacter Pylori Eradication in Indian Population. VECTOR Trial - Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication

NCT06959368 is registered in ClinicalTrials.gov with Asian Institute of Gastroenterology, India as lead sponsor.

NCT NCT06959368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06959368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Controlled Trial Comparing Vonoprazan Triple Therapy (Vonoprazan, Amoxicillin, Clarithromycin), and Standard Triple Therapy (Esomeprazole, Amoxicillin, Clarithromycin) for Helicobacter Pylori Eradication in Indian Population. VECTOR Trial - Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication
Lead sponsor
Asian Institute of Gastroenterology, India
Phase
Phase 4
Overall status
Recruiting
Start date
March 25, 2025
Completion date
March 25, 2026
Enrollment
484 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection